Lifeline for rare disease patients denied access to vital drug

This study provides continued access to the drug metreleptin for people with a rare condition called generalized lipodystrophy who have previously received it through NIH research and cannot get it through normal channels in their home country. It aims to monitor the long-term safety and effectiveness of metreleptin in controlling serious metabolic problems like severe diabetes and high blood fat levels. Participants receive the drug via daily injections and return for periodic check-ups at the NIH to track their health.